Melanoma & Skin Cancer | Specialty

Dual-Targeted Therapy for BRAF-Mutant Melanoma

October 31st 2016

Risk Stratification for Advanced Melanoma

October 31st 2016

Neoadjuvant Therapy for Melanoma

October 31st 2016

Adjuvant PD-(L)1 Inhibitors for Melanoma

October 31st 2016

Adjuvant Therapy for Melanoma

October 31st 2016

Surgical Management of Locoregional Melanoma

October 31st 2016

EMA Accepts Avelumab Application for Merkel Cell Carcinoma

October 31st 2016

The European Medicines Agency has accepted and validated a marketing authorization application for avelumab as a treatment for patients with metastatic Merkel cell carcinoma.

Dr. Postow on Advancements of Immunotherapy in Melanoma

October 28th 2016

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the exciting advancements seen with immunotherapy in the treatment of patients with melanoma.

Dr. Saenger on the Importance of Biomarkers When Administering Immunotherapy

October 27th 2016

Yvonne Saenger, MD, director of Melanoma Immunotherapy at Columbia University Medical Center, discusses the importance of developing accurate biomarkers when it comes to administering immunotherapy.

Dr. Jeffery S. Weber on Sequencing of Nivolumab, Ipilimumab in Metastatic Melanoma

October 25th 2016

Jeffery S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discuses the key takeaways from the phase II CheckMate-064 trial, in which patients were randomized to receive either nivolumab followed by ipilimumab followed by nivolumab maintenance therapy, or ipilimumab followed by nivolumab and maintenance therapy with nivolumab.

Dr. Luke on Immunotherapy Diagnostics in Melanoma

October 20th 2016

Jason Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses the various methods involved in immunotherapy diagnostics in the treatment landscape of melanoma.

Long-Term Follow-Up Supports Frontline Dabrafenib/Trametinib in Melanoma

October 20th 2016

Co-inhibition of BRAF and MEK pathways with dabrafenib and trametinib continued to be superior to sole BRAF inhibition with vemurafenib in patients with unresectable metastatic melanoma at 3 years.

Immunotherapy Combos, Novel Diagnostics Emerging in Melanoma

October 17th 2016

Jason Luke, MD, discusses some of the exciting research that is happening across the field of immunotherapy in melanoma, including combination strategies, novel agents, and next-generation diagnostics.

Mature Data Sustain Frontline OS Benefit of Pembrolizumab in Melanoma

October 17th 2016

A final analysis of the overall survival data from the KEYNOTE-006 trial showed that frontline pembrolizumab was superior to ipilimumab in the treatment of patients with advanced melanoma.

Dr. Robert on Next Steps Following the Phase III COMBI-v Study in Melanoma

October 14th 2016

Caroline Robert, MD, PhD, Head of Dermatology, Institute Gustave-Roussy, discusses the next steps following the results of the phase III COMBI-v study in BRAF-mutant melanoma.

Dr. Jason Luke on Potential for IDO Inhibitors in Melanoma

October 13th 2016

Jason Luke, MD, Assistant Professor of Medicine, The University of Chicago Medicine, discusses IDO inhibitors in melanoma.

Dr. Flaherty on Resistance in BRAF-Mutant Melanoma

October 11th 2016

Keith T. Flaherty, MD, director of Developmental Therapeutics at the Cancer Center of Massachusetts General Hospital, discusses resistance that develops in patients with BRAF-mutant melanoma.

Dr. Robert on the Phase III COMBI-v Study in BRAF-Mutant Melanoma

October 8th 2016

Caroline Robert, MD, PhD, Head of Dermatology, Institute Gustave-Roussy, discusses the results of the phase III COMBI-v study in BRAF-mutant melanoma during an interview at the ESMO 2016 Congress.

Adjuvant Ipilimumab Improves Survival in High-Risk Melanoma

October 8th 2016

Treatment with ipilimumab reduced the risk of death by 28% versus placebo in patients with high-risk stage III melanoma.

Thousands of Melanoma Patients in Europe Not Receiving Novel Agents

October 7th 2016

Over one-fourth of patients with metastatic melanoma in Europe do not have access to groundbreaking therapies that could extend their lives.